Induction of "antigen silencing" in melanomas by oncostatin M: Down-modulation of melanocyte antigen expression

Molecular Cancer Research

Volumn 1, Issue 6, 2003, Pages 411-419

  Durda, Paul J ^a,b,c   Dunn, Ian S ^b,d   Rose, Lenora Boyle ^a   Butera, David ^a,b   Benson, Elizabeth M ^d   Pandolfi, Franco ^e   Kurnick, James T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CytoCure LLC   (United States)

^c BOSTON BIOMEDICAL RESEARCH INSTITUTE   (United States)

^d WESTMEAD HOSPITAL   (Australia)

^e CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CELL SURFACE RECEPTOR; CYTOKINE; GLYCOPROTEIN GP 100; GLYCOPROTEIN GP 130; MELAN A; MONOPHENOL MONOOXYGENASE; ONCOSTATIN M; TRANSCRIPTION FACTOR; TYROSINASE RELATED PROTEIN 1; TYROSINASE RELATED PROTEIN 2;

ANTIGEN EXPRESSION; ARTICLE; CELL DIFFERENTIATION; CELL LINE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MELANOCYTE; MELANOMA; MELANOMA CELL; MICROPHTHALMIA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL;

ANTIGENS, CD; ANTIGENS, NEOPLASM; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL LINEAGE; DOWN-REGULATION; HUMANS; MELANOCYTES; MELANOMA; ONCOSTATIN M; PEPTIDES; RECEPTORS, CYTOKINE; RECEPTORS, ONCOSTATIN M; RNA, MESSENGER;

EID: 12444279626     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Marchand, M., van Baren, N., Weynants, P., Brichard, V., Dreno, B., Tessier, M. H., Rankin, E., Parmiani, G., Arienti, F., Humblet, Y., Bourlond, A., Vanwijck, R., Lienard, D., Beauduin, M., Dietrich, P. Y., Russo, V., Kerger, J., Masucci, G., Jager, E., De Greve, J., Atzpodien, J., Brasseur, F., Coulie, P. G., van der Bruggen, P., and Boon, T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer, 80: 219-230, 1999.
2. Minev, B. R., Chavez, F. L., and Mitchell, M. S. Cancer vaccines: novel approaches and new promise. Pharmacol. & Ther., 81: 121-139, 1999.
3. Rosenberg, S. A. Progress in human tumour immunology and immunotherapy. Nature, 411: 380-384, 2001.
4. Maeurer, M. J., Gollin, S. M., Martin, D., Swaney, W., Bryant, J., Castelli, C., Robbins, P., Parmiani, G., Storkus, W. J., and Lotze, M. T. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J. Clin. Invest., 98: 1633-1641, 1996.
5. Marincola, F., Jaffee, E., Hicklin, D., and Ferrone, S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol., 74 181-273, 2000.
6. Jager, E., Ringhoffer, M., Altmannsberger, M., Arnd, M., Karbach, J., Jager, D., Oesch, F., and Knuth, A. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer, 71: 142-147, 1997.
7. Anichini, A., Molla., A., Mortarini, R., Tragni G., Bersani, I., DiNicola, M., Gianni, A., Pilotti, S., Dunbar, R., Cerundolo, V., and Parmiani, G. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J. Exp. Med., 90: 651-667, 1999.
8. Chomez, P., De Backer, O., Bertrand, M., De Plaen, E., Boon, T., and Lucas, S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res., 61: 5544-5551, 2001.
9. Rivoltini, L., Kawakami, Y., Sakaguchi, K., Southwood, S., Sette, A., Robbins, P., Marincola, F., Salgaller, M., Yannelli, J., and Appella E. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol., 154: 2257-2265, 1995.
10. Kawakami, Y. and Rosenberg, S. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy, Int. Rev. Immunol., 14: 173-192, 1997.
11. Yee, C., Thompson, J. A., Roche, P., Byrd, D. R., Lee, P. P., Piepkom, M., Kenyon, K., Davis, M. M., Riddell, S. R., and Greenberg, P. D. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J. Exp. Med., 192: 1637-1644, 2000.
12. Chen, L., Ashe, S., Brady, W., Hellstrom, I., Hellstrom, K., Ledbetter, J., McGowan, P., and Linsley, P. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell, 71: 1093-1102, 1992.
13. Townsend, S. E. and Allison, J. P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science, 259: 368-370, 1993.
14. Kumick, J. T., Ramirez-Montagut, T., Boyle, L. A., Andrews, D. M., Pandolfi, F., Durda, P. J., Butera, D., Dunn, I. S., Benson, E. M., Gobin, S. J., and van den Elsen, P. J. A novel autocrine pathway of tumor escape from immune recognition: melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage melan-A/MART-1 antigen through down-modulation of its promoter. J. Immunol., 167: 1204-1211, 2001.
15. Hishii, M., Kumick, J., Ramirez-Montagut, T., and Pandolfi, F. Studies of the mechanism of cytolysis by tumour-infiltrating lymphocytes. Clin. Exp. Immunol., 116: 388-394, 1999.
16. Pandolfi, F., Trentin, L., Boyle, L. A., Stamenckovic, I., Byers, H. R., Colvin, R. B., and Kumick, J. T. Expression of cell adhesion molecules in human melanoma cell lines and their role in lymphocyte mediated cytotoxicity. Cancer, 69: 1165-1173, 1992.
17. Pandolfi, F., Boyle, L. A., Trentin, L., Kumick, J. T., Isselbacher, K. J., and Gattoni Celli, S. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition. Cancer Res., 51: 3164-3169, 1991.
18. Hishii, M., Andrews, D., Boyle, L., Wong, J., Pandolfi, F., van den Elsen, P., and Kumick, J. Accumulation of the same anti-melanoma T cell clone in two different metastatic sites. Proc. Natl. Acad. Sci. USA, 94: 1378-1383, 1997.
19. Mihm, M. C., Jr., Clemente, C. G., and Cascinelli, N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab. Invest., 74: 43-47, 1996.
20. Kawakami, Y., Suzuki, Y., Shofuda, T., Kiniwa, Y., Inozume, T., Dan, K., Sakurai, T., and Fujita, T. T cell immune responses against melanoma and melanocytes in cancer and autoimmunity. Pigment Cell Res., 13: 163-169, 2000.
21. Shibahara, S., Yasumoto, K., Amae, S., Udono, T., Watanabe, K., Saito, H., and Takeda, K. Regulation of pigment cell-specific gene expression by MITF. Pigment Cell Res., 13: 98-102, 2000.
22. King, R., Googe, P. B., Weilbaecher, K. N., Mihm, M. C., Jr., and Fisher, D. E. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors. Am. J. Surg. Pathol., 25: 51-57, 2001.
23. Tachibana, M. MITF: a stream flowing for pigment cells. Pigment Cell Res., 13: 230-240, 2000.
24. Yasumoto, K., Amae, S., Udono, T., Fuse, N., Takeda, K., and Shibahara, S. A big gene linked to small eyes encodes multiple Mitf isoforms: many promoters make light work. Pigment Cell Res., 11: 329-336, 1998.
25. Goding, C. and Fisher, D. Regulation of melanocyte differentiation and growth. Cell Growth & Differ., 8: 935-940, 1997.
26. Goding, C. R. Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes Dev., 14: 1712-1728, 2000.
27. Rhee, I., Bachman, K. E., Park, B. H., Jair, K. W., Yen, R. W., Schuebel, K. E., Cui, H., Feinberg, A. P., Lengauer, C., Kinzler, K. W., Baylin, S. B., and Vogelstein, B. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature, 416: 552-556, 2002.
28. Tuschl, T., Zamore, P. D., Lehmann, R., Bartel, D. P., and Sharp, P. A. Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev., 13: 3191-3197, 1999.
29. Paddison, P. J., Caudy, A. A., Bernstein, E., Hannon, G. J., and Conklin, D. S. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev., 16: 948-958, 2002.
30. Yeh, J. H., Spicuglia, S., Kumar, S., Sanchez-Sevilla, A., Ferrier, P., and Imbert, J. Control of IL-2Rα gene expression: structural changes within the proximal enhancer/core promoter during T-cell development. Nucleic Acids Res., 30: 1944-1951, 2002.
31. Shang, Y. and Brown, M. Molecular determinants for the tissue specificity of SERMs. Science, 295: 2465-2468, 2002.
32. Vassallo, M. F. and Tanese, N. Isoform-specific interaction of HP1 with human TAFII130. Proc. Natl. Acad. Sci. USA, 99: 5919-5924, 2002.
33. Mendez, R., Serrano, A., Jager, E., Maleno, I., Ruiz-Cabello, F., Knuth, A., and Garrido, F. Analysis of HLA class 1 expression in different metastases from two melanoma patients undergoing peptide immunotherapy. Tissue Antigens, 57: 508-519, 2001.
34. Ogawa, H., Ishiguro, K., Gaubatz, S., Livingston, D. M., and Nakatani, Y. A complex with chromatin modifiers that occupies E2F- and Myc-responsive genes in G0 cells. Science, 296: 1132-1136, 2002.
35. Mizuno, K., Osada, H., Konishi, H., Tatematsu, Y., Yatabe, Y., Mitsudomi, T., Fujii, Y., and Takahashi, T. Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. Oncogene, 21: 2328-2333, 2002.
36. Yang, X., Phillips, D. L., Ferguson, A. T., Nelson, W. G., Herman, J. G., and Davidson, N. E. Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-αnegative breast cancer cells. Cancer Res., 61: 7025-7029, 2001.
37. Liu, P. T., Ta, T. V. and Villarete, L. H. High-yield expression and purification of human interferon α-1 in Pichia pastoris. Protein Expr. Purif., 22: 381-387, 2001.
38. Gambino, G. M., Beck-Peccoz, P., Borgato, S., Faglia, G., Spada, A., and Persani, L. Bioactivity and glycosylation of circulating prolactin in various physiological and pathological conditions. Pituitary, 2: 225-231, 1999.
39. Bonig, H., Silbermann, S., Weller, S., Kirschke, R., Korholz, D., Janssen, G., Gobel, U., and Nurnberger, W. Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF) - results of a prospective randomised monocentre study. Bone Marrow Transplant., 28: 259-264, 2001.
40. Heinrich, P. C., Behrmann, I., Muller-Newen, G., Schaper, F., and Graeve, L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J., 334: 297-314, 1998.
41. Chevalier, S., Fourcin, M., Robledo, O., Wijdenes, J., Pouplard-Barthelaix, A., and Gascan, H. Interleukin-6 family of cytokines induced activation of different functional sites expressed by gp130 transducing protein. J. Biol. Chem., 271: 14764-14772, 1996.
42. Amae, S., Fuse, N., Yasumoto, K., Sato, S., Yajima, I., Yamamoto, H., Udono, T., Durlu, Y. K., Tamai, M., Takahashi, K., and Shibahara, S. Identification of a novel isoform of microphthalmia-associated transcription factor that is enriched in retinal pigment epithelium. Biochem. Biophys. Res. Commun., 247: 710-715, 1998.
43. King, R., Weilbaecher, K. N., McGill, G., Cooley, E., Mihm, M., and Fisher, D. E. Microphthalmia transcription factor. A sensitive and specific melanocyte marker for melanoma diagnosis. Am. J. Pathol., 155: 731-738, 1999.
44. Wong, L. H., Sim, H., Chatterjee-Kishore, M., Hatzinisiriou, I., Devenish, R. J., Stark, G., and Ralph, S. J. Isolation and characterization of a human STAT1 gene regulatory element. Inducibility by interferon (IFN) types I and II and role of IFN regulatory factor-1. J. Biol. Chem., 277: 19408-19417, 2002.
45. Zarling, J. M., Shoyab, M., Marquardt, H., Hanson, M. B., Lioubin, M. N., and Todaro, G. J. Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. Proc. Natl. Acad. Sci. USA, 83: 9739-9743, 1986.
46. Kozlowska, K., Cichorek, M., and Zarzeczna, M. Estimation of oncostatin M (OSM) secretion by peritoneal macrophages with regard to the progression of transplantable melanomas. Neoplasma, 45: 369-372, 1998.
47. Gibbs, P., Chen, Q., and Robinson, W. A. Effects of oncostatin M and tamoxifen on human melanoma cells. Melanoma Res., 8: 221-226, 1998.
48. Lu, C., Rak, J. W., Kobayashi, H., and Kerbel, R. S. Increased resistance to oncostatin M-induced growth inhibition of human melanoma cell lines derived from advanced-stage lesions. Cancer Res., 53: 2708-2711, 1993.
49. Giacomini, P., Fraioli, R., Nistico, P., Tecce, R., Nicotra, M. R., Di Filippo, F., Fisher, P. B., and Natali, P. G. Modulation of the antigenic phenotype of early-passage human melanoma cells derived from multiple autologous metastases by recombinant human leukocyte, fibroblast and immune interferon. Int. J. Cancer, 46: 539-545, 1990.
50. Le Poole, I. C., Piker, A. I., Quevedo, M. E., Stennett, L. S., Wang, E., Marincola, F. M., Kast, W. M., Robinson, J. K., and Nickoloff, B. J. Interferon-γ reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. Am. J. Pathol., 160: 521-528, 2002.
51. Chen, Y., Stockert, E., Jungbluth, A., Tsang, S., Coplan, K., Scanlan, M., and Old, L. Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc. Natl. Acad. Sci. USA, 93(12): 5915-5919, 1996.